e-Therapeutics PLC - Oxford, England-based computer-based drug discovery - Files five new patent filings to protect its proprietary RNAi platform technology for liver gene silencing. Development in platform relating to GalNAc-conjugated short inferring RNA construct designs, including around stabilising chemical modifications enabling specific liver cell targeting.
"Since our capital raise in May, we have made excellent progress in all areas of the company," says Chief Executive Ali Mortazavi. "We expect to present data from our RNAi platform in our interim results announcement on October 26 when the in vivo characterisation studies will have been completed."
In May, raised GBP22.5 million by issuing 93.8 million shares at 24 pence each. At the time, said proceeds would go towards several initiatives, including expanding the company's proprietary, disease-agnostic, drug discovery and development platform capabilities and asset pipeline.
Current stock price: 33.10 pence, up 5.3% on Monday afternoon
Year-to-date change: up 83%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
E-therapeutics (ETX)